Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Surrozen, Inc.
  6. Notizie
  7. Altre lingue
    SRZN   US86889P1093

SURROZEN, INC.

(SRZN)
  Rapporto
Tempo differito Nasdaq  -  22:00:00 07/02/2023
0.7435 USD   -3.43%
12/01Transcript : Surrozen, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 07:30 AM
CI
2022I principali ribassisti del mercato
MT
2022Vendite al dettaglio più deboli del previsto, la Fed hawkish mandano i futures azionari statunitensi in forte ribasso
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su SURROZEN, INC.
12/01Surrozen: Targeted Regeneration Presentation
05/01Surrozen, Inc./de: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or ..
04/01Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022Top Premarket Decliners
2022Surrozen, Inc./de: Other Events (form 8-K)
2022Surrozen: Repurchase of Common Stock and Warrants to Purchase Common Stock - Form 8-K
2022Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower
2022Tranche Update on Surrozen, Inc.'s Equity Buyback Plan announced on December 15, 2022.
2022Surrozen, Inc. announces an Equity Buyback for 1,310,496 shares, for $2.7 million.
2022Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move..
2022Top Premarket Gainers
2022Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,4..
2022Surrozen Files $200 Million Mixed Shelf
2022Surrozen, Inc. authorizes a Buyback Plan.
2022Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopath..
2022SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu..
2022Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
2022Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroente..
2022Surrozen, Boehringer Ingelheim to Support Research, Development of Retinal Diseases Tre..
2022Surrozen, Inc./de: Entry into a Material Definitive Agreement (form 8-K)
2022Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agoni..
2022Surrozen, Inc. Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt..
2022Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating t..
2022Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating t..
2022Surrozen: SZN-1326 13-week GLP Toxicity Studies
2022Surrozen: SZN-043 Hepatocyte Proliferation in 14-day daily dosing Edu-labeling study
2022SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu..
2022Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
2022Surrozen: Reports Second Quarter 2022 Financial Results - Form 8-K
2022Surrozen Reports Second Quarter 2022 Financial Results
2022Surrozen, Inc.(NasdaqCM:SRZN) added to Russell Microcap Value In..
2022Surrozen, Inc.(NasdaqCM:SRZN) added to Russell 3000E Index
2022Surrozen, Inc.(NasdaqCM:SRZN) added to Russell Microcap Index
2022Surrozen, Inc.(NasdaqCM:SRZN) added to Russell 3000E Value Index
2022Surrozen, Inc./de: Submission of Matters to a Vote of Security Holders, Financial Stateme..
2022Surrozen Doses First Patient in Early Trial of SZN-043 to Treat Alcoholic Hepatitis
2022Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hep..
2022Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcohol..
2022Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
2022Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week
2022Surrozen Begins Dosing in Phase 1 Study of Ulcerative Colitis Treatment; Shares Rise Ea..
2022Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe ..
2022Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to S..
2022Surrozen: SZN-043 Induced Quick and Robust Hepatocyte Proliferation in a 14-Day Daily Dos..
2022Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology De..
2022SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu..
2022Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Surrozen Reports First Quarter 2022 Financial Results
2022Surrozen to Present at the BofA Securities 2022 Healthcare Conference
2022Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Re..
2022Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabe..
2022Surrozen: Association for Research in Vision and Ophthalmology
2022SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu..
2022Surrozen: Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
2022Surrozen, Inc./de: Results of Operations and Financial Condition, Shareholder Director No..
2022Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
2022Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
2022Surrozen, Inc./de: Entry into a Material Definitive Agreement, Unregistered Sale of Equit..
2022Surrozen: Pep Talk 2022 Poster
2022Surrozen: Investor Presentation January 2022
2022Surrozen, Inc./de: Other Events (form 8-K)
2022Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research P..
2022Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
2021Surrozen: Reports Third Quarter 2021 Financial Results - Form 8-K
2021Surrozen Reports Third Quarter 2021 Financial Results
2021Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
2021Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
2021Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the A..
2021Surrozen, Inc. Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021,..
2021Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
2021Surrozen : Drug Candidate Shows Potential in Bowel Disease Based on Preclinical..
2021Surrozen: Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gas..
2021Surrozen: Announces Appointment of Liz Nguyen as Vice President and Head of Human Resourc..
2021Surrozen, Inc. Announces Appointment of Liz Nguyen as Vice President and Head of Human ..
2021Surrozen, Inc.(NasdaqCM:SRZN) added to S&P TMI Index
2021Top Midday Gainers
2021Surrozen : Stock Jumps after Stifel Begins Coverage
2021Surrozen: Unaudited Condensed Interim Financial Statements for the Three and Six Months E..
2021Consonance-HFW Acquisition Corp.(NasdaqCM:SRZN) add..
2021Consonance Hfw Acquisition: Common stock and warrants to commence trading on Nasdaq on Au..
2021Consonance Hfw Acquisition: Surrozen Debuts as Publicly Traded Leader in Wnt Biology and ..
2021Surrozen, Inc. announced that it has received $120.2 million in funding from Consonance..
2021Surrozen, Inc. completed the acquisition of Consonance-HFW Acquisition Corp. from Conso..
2021Consonance-Hfw Acquisition Corp. Reports Earnings Results for the Second Quarter Ended ..
2021Consonance Hfw Acquisition: Business Combination Agreement (Form 8-K)
2021Consonance Hfw Acquisition: New Surrozen to Trade on Nasdaq as "SRZN" (Form 8-K)
2021Consonance Hfw Acquisition: New Surrozen to Trade on Nasdaq as “SRZN”
2021Consonance-Hfw Acquisition Corp. Reports Earnings Results for the First Quarter Ended M..
2021Certain Class B Ordinary Shares of Consonance-HFW Acquisition Corp. are subject to a Lo..
2021Surrozen, Inc. Auditor Raises 'Going Concern' Doubt
2021Consonance HFW Acquisition : Surrozen Agrees to Merge With SP..
2021Consonance Hfw Acquisition: Surrozen and Consonance-HFW Acquisition Corp. Announce Busine..
2021Surrozen, Inc. announced that it expects to receive $120.2 million in funding from Cons..
2021Surrozen, Inc. signed a definitive agreement to acquire Consonance-HFW Acquisition Corp..
2020Consonance-HFW Acquisition Corp. announced that it has received $4.1 million in funding..
2020Consonance-HFW Acquisition Corp. has completed an IPO in the amount of $80 million.
2020Consonance-HFW Acquisition Corp. has filed an IPO in the amount of $100 million.
2020Consonance-HFW Acquisition Corp. announced that it expects to receive $4.5 million in f..
2016Surrozen, Inc. announced that it expects to receive $33.555555 million in funding